Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment.

BACKGROUND Specificity and sensitivity are essential in assays for immunogenicity assessment of biotherapeutics. Nonspecific interactions from excess therapeutic or anti-therapeutic antibody, soluble ligands (e.g., target receptor), or serum proteins associated with autoimmune conditions (e.g., rheumatoid factor) in samples can impact the detection of a true anti-therapeutic response. RESULTS Electrochemiluminescence-based bridging assay formats could eliminate the interference due to rheumatoid factor with no pretreatment with Melon Gel™ or aggregated IgG. The interference due to soluble factors was not platform specific for the four therapeutics evaluated in this study. CONCLUSION Melon Gel pretreatment and avidin high-bind (Meso Scale Discovery) plates can effectively reduce interference due to rheumatoid factor in ELISA- and electrochemiluminescence-based assays, respectively. Excess levels of therapeutic and anti-therapeutic antibodies in bridging assays can impact assay specificity.

[1]  Chad Ray,et al.  Identification and inhibition of drug target interference in immunogenicity assays. , 2010, Journal of immunological methods.

[2]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[3]  Jana S Chain,et al.  An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. , 2007, Journal of immunological methods.

[4]  A. Mire-Sluis,et al.  An overview of scientific and regulatory issues for the immunogenicity of biological products. , 2003, Developments in biologicals.

[5]  Eugen Koren,et al.  An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. , 2005, Journal of immunological methods.

[6]  A. Mire-Sluis,et al.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. , 2002, Current pharmaceutical biotechnology.

[7]  J. Honour,et al.  Unusual results from immunoassays and the role of the clinical endocrinologist , 2006, Clinical endocrinology.

[8]  L. Old,et al.  Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. , 2001, Cancer research.

[9]  A. Butch.  Dilution protocols for detection of hook effects/prozone phenomenon. , 2000, Clinical chemistry.

[10]  C. Aybay,et al.  Development of a rapid, single-step procedure using protein G affinity chromatography to deplete fetal calf serum of its IgG and to isolate murine IgG1 monoclonal antibodies from supernatants of hybridoma cells. , 2000, Journal of immunological methods.

[11]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[12]  N. Chirmule,et al.  Assessing specificity for immunogenicity assays. , 2009, Bioanalysis.

[13]  D. Speicher,et al.  Depletion of multiple high‐abundance proteins improves protein profiling capacities of human serum and plasma , 2005, Proteomics.

[14]  F. Legay,et al.  Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. , 2008, Journal of immunological methods.

[15]  Viswanath Devanarayan,et al.  Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.

[16]  Arunan Kaliyaperumal,et al.  Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab , 2007, The Journal of Immunology.

[17]  Vibha Jawa,et al.  Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. , 2005, Clinical chemistry.

[18]  Daniel Mytych,et al.  Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples , 2003, Current medical research and opinion.